NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01419665,"GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)",https://clinicaltrials.gov/study/NCT01419665,ASSIST_FL,COMPLETED,"The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.",YES,Follicular Lymphoma,BIOLOGICAL: GP2013|BIOLOGICAL: rituximab,"Overall Response Rate (ORR), ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review., 24 weeks","To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period, 24 weeks|To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period, 24 weeks|To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization, Number of participants with progression free survival events, 3 years|To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths, OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up., 3 years|To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab), number of participants with confirmed positive ADA, 24 weeks, 3 years|To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max), C max

For descriptive purposes only, no hypothesis testing, day 63|To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough), C through

For descriptive purposes only, no hypothesis testing, day 63|To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy, AUEC (0-21d)

For descriptive purposes only, no hypothesis testing, 21 days",,Sandoz,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,629,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",GP13-301|2010-019522-13,2011-12-01,2015-07-10,2018-01-22,2011-08-18,2021-05-14,2021-05-14,"Investigative site, La Plata, Argentina|Investigative site, Rosario, Argentina|Investigative site, San Miguel de Tucuman, Argentina|Investigative site, Adelaide, Australia|Investigative site, Ballarat, Australia|Investigative site, Epping, Australia|Investigative site, Footscray, Australia|Investigative site, Wodonga, Australia|Investigative site, Graz, Austria|Investigative site, Wien, Austria|Investigative site, Barretos, Brazil|Investigator site, Barretos, Brazil|Investigative site, Botucatu, Brazil|Investigative site, Campinas, Brazil|Investigative site, Curitiba, Brazil|Investigative site, Florianopolis, Brazil|Investigative site, Fortaleza, Brazil|Investigative site, Goiania, Brazil|Investigative site, Jau, Brazil|Investigative site, Passo Fundo, Brazil|Investigative site, Porto Alegre, Brazil|Investigative Site, Rio de Janeiro, Brazil|Investigative site, Santo Andre, Brazil|Investigative site, Sao Paulo, Brazil|Investigative site, Sorocaba, Brazil|Investigative site, Pleven, Bulgaria|Investigative site, Plovdiv, Bulgaria|Investigative site, Ruse, Bulgaria|Investigative site, Sofia, Bulgaria|Investigative site, Varna, Bulgaria|Investigative site, Medellin, Colombia|Investigative site, Monteria, Colombia|Investigative site, Colmar, France|Investigative site, Nimes, France|Investigative site, Strasbourg, France|Investigative site, Bad Saarow, Germany|Investigative site, Koblenz, Germany|Investigative site, Athens, Greece|Investigative site, Ioannina, Greece|Investigative site, Larissa, Greece|Investigative site, Patras, Greece|Investigative site, Györ, Hungary|Investigative site, Kaposvar, Hungary|Investigative site, Ahmedabad, India|India, Amritsar, India|Investigative site, Aurangabad, India|Investigative site, Bangalore, India|Investigative site, Chennai, India|Investigative site, Hyderabad, India|Investigative site, Kolkata, India|Investigtive site, Kolkata, India|Investigative site, Madurai, India|Investigative site, Mumbai, India|Investigative site, Nashik, India|Investigative site, New Delhi, India|Investigative site, Pune, India|Investigative site, Surat, India|Investigative site, Trivandrum, India|Investigative site, Vellore, India|Investigative site, Dublin, Ireland|Investigative site, Limerick, Ireland|Investigative site, Waterford, Ireland|Investigative site, Ashkelon, Israel|Investigative site, Nahariya, Israel|Investigative site, Bari, Italy|Investigative site, Firenze, Italy|Investigative site, Meldola, Italy|Investigative site, Milano, Italy|Investigative site, Palermo, Italy|Investigative site, Pavia, Italy|Investigative site, Pescara, Italy|Investigative site, Piacenza, Italy|Investigative site, Ravenna, Italy|Investigative site, Reggio Calabria, Italy|Investigative site, Varese, Italy|Investigative site, Aomori, Japan|Investigative site, Fukuoka, Japan|Investigative site, Gifu, Japan|Investigative site, Kagoshima, Japan|Investigative site, Kitakyushu, Japan|Investigative site, Kobe, Japan|Investigative site, Komaki, Japan|Investigative site, Matsuyama, Japan|Investigative site, Ogaki, Japan|Investigative site, Okayama, Japan|Invstigative site, Omura, Japan|Investigative site, Saga, Japan|Investigative site, Tachikawa, Japan|Investigative site, Ōtake, Japan|Investigative site, Alor Setar, Malaysia|Investigative site, Ampang, Malaysia|Investigative site, George Town, Malaysia|Investigative site, Ipoh, Malaysia|Investigative site, Johor Bahru, Malaysia|Investigative site, Klang, Malaysia|Investigative site, Kuala Lumpur, Malaysia|Investigative site, Kuching, Malaysia|Investigative site, Melaka, Malaysia|Investigative site, Pulau Pinang, Malaysia|Investigative site, Subang Jaya, Malaysia|Investigative site, Amsterdam, Netherlands|Investigative site, Delft, Netherlands|Investigative site, Gouda, Netherlands|Investigative site, Heerlen, Netherlands|Investigative site, Rotterdam, Netherlands|Investigative site, Schiedam, Netherlands|Investigative site, Sittard, Netherlands|Investigative site, Zwolle, Netherlands|Investigative site, Lima, Peru|Investigative site, Brzozow, Poland|Investigative site, Bydgoszcz, Poland|Investigative site, Chorzow, Poland|Investigative site, Krakow, Poland|Investigative site, Lublin, Poland|Investigative site, Warszawa, Poland|Investigative site, Braga, Portugal|Investigative site, Coimbra, Portugal|Investigative site, Lisboa, Portugal|Investigative site, Porto, Portugal|Investigative site, Brasov, Romania|Investigative site, Bucharest, Romania|Investigative site, Cluj-Napoca, Romania|Investigative site, Iasi, Romania|Investigative site, Timisoara, Romania|Investigative site, Arkhangelsk, Russian Federation|Investigative site, Chelyabinsk, Russian Federation|Investigative site, Krasnodar, Russian Federation|Investigative site, Kursk, Russian Federation|Investigative site, Moscow, Russian Federation|Investigative site, Nizhniy Novgorod, Russian Federation|Investigative site, Rostov-on -Don, Russian Federation|Investigative site, St. Petersburg, Russian Federation|Investigative site, Cape Town, South Africa|Investigative site, George, South Africa|Investigative site, Johannesburg, South Africa|Investigative site, Port Elizabeth, South Africa|Investigative site, Pretoria, South Africa|Investigative site, Barcelona, Spain|Investigative site, Madrid, Spain|Investigative site, Oviedo, Spain|Investigative site, San Sebastian, Spain|Investigative site, Sevilla, Spain|Investigative site, Zaragoza, Spain|Investigative site, Cherkasy, Ukraine|Investigative site, Dnipropetrovsk, Ukraine|Investigative site, Donetsk, Ukraine|Investigative site, Ivano-Frankivsk, Ukraine|Investigative site, Kharkiv, Ukraine|Investigative site, Kyiv, Ukraine|Investigative site, Lviv, Ukraine|Investigative site, Eastbourne, United Kingdom|Investigative site, London, United Kingdom|Investigative site, Worthing, United Kingdom",
